Comparative-Effectiveness Research to Aid Population Decision Making by Relating Clinical Outcomes and Quality-Adjusted Life Years

Clinical Therapeutics

Volumn 35, Issue 4, 2013, Pages 364-370

  Campbell, Jonathan D ^a   Zerzan, Judy ^b   Garrison, Louis P ^c   Libby, Anne M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Colorado Department of Health Care Policy and Financing ^*  (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CER methods; Comparative effectiveness research; Decision analysis; Framework; Quality adjusted life years

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE COURSE; EXTERNAL VALIDITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

COMPARATIVE EFFECTIVENESS RESEARCH; DECISION MAKING; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS;

EID: 84876299898     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.02.011     Document Type: Article

References (29)

1. American Recovery and Reinvestment Act of 2009 Accessed February 7, 2013. http://www.hhs.gov/recovery/programs/cer/recoveryacttext.html.
2. Earnshaw S.R., Graham J., Oleen-Burkey M., Castelli-Haley J., Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy 2009, 7:91-108.
3. What is comparative effectiveness research Agency for Healthcare Research and Quality, Accessed February 7, 2013. http://effectivehealthcare.ahrq.gov/index.cfm/what-is-comparative-effectiveness-research1.
4. Zwarenstein M., Treweek S., Gagnier J.J., et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008, 337:a2390.
5. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
6. Kattan M.W. Comparative effectiveness: a table of expected benefits and harms. Med Decis Making 2009, 29:NP3-NP5.
7. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.
8. Cost-Effectiveness Analysis Registry, Accessed February 7, 2013. https://research.tufts-nemc.org/cear4/default.aspx.
9. Weinstein M.C., O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies. Value Health 2003, 6:9-17.
10. Garrison L.P., Towse A., Bresnahan B.W. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) 2007, 26:684-695.
11. Hughes D.A., Bayoumi A.M., Pirmohamed M. Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?. Clin Pharmacol Ther 2007, 82:123-127.
12. Cross J.T., Veenstra D.L., Gardner J.S., Garrison L.P. Can modeling of health outcomes facilitate regulatory decision making?. The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. Clin Pharmacol Ther 2011, 89:429-436.
13. Garrison L.P. Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?. PharmacoEconomics 2010, 28:855-865.
14. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999, 18:341-364.
15. National Institute for Clinical Excellence, Accessed May 25, 2010. http://www.nice.org.uk.
16. Gold M.R., Siegel J.E., Russell L.B., Wienstein M.C. Cost-Effectiveness in Health and Medicine 1996, Oxford Press Inc., New York.
17. Miller W., Robinson L.A., Lawrence R.S. Valuing Health for Regulatory Cost-Effectiveness Analysis 2006, National Academies Press, Washington.
18. Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes 1997, Oxford University Press Inc., New York.
19. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008, 372:2152-2161.
20. Chandra A., Jena A.B., Skinner J.S. The pragmatist's guide to comparative effectiveness research. J Econ Perspect 2011, 25:27-46.
21. Claxton K., Lacey L.F., Walker S.G. Selecting treatments: a decision theoretic approach. J Royal Stat Soc A 2000, 163:211-226.
22. The Patient Protection and Affordable Care Act. PL 111-148 March 23, 2010.
23. Determinants of health economic decisions in actual practice: the role of behavioral economics. Summary of the presentation given by Professor Daniel Kahneman at the ISPOR 10th Annual International Meeting First Plenary Session, May 16, 2005, Washington, DC, USA. Value Health 2006, 9:65-67.
24. McGregor M., Caro J.J. QALYs: are they helpful to decision makers?. PharmacoEconomics 2006, 24:947-952.
25. Dreaper J. Researchers claim NHS drug decisions 'are flawed' Accessed February 7, 2013. http://www.bbc.co.uk/news/health-21170445?goback=.gde_39902_member_208040063.
26. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990, 16:199-208. EuroQol Group.
27. Neumann P.J., Weinstein M.C. Legislating against use of cost-effectiveness information. N Engl J Med 2010, 363:1495-1497.
28. Neumann P.J. What next for QALYs?. JAMA 2011, 305:1806-1807.
29. Stang A., Poole C., Bender R. Common problems related to the use of number needed to treat. J Clin Epidemiol 2010, 63:820-825.